• Search
  • Helpdesk
  • Sales contact
Get your demo
☰

Case study

Tackling the specificities of NASH/MASH clinical trials

Metabolic
Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating chronic illness that significantly impairs patients' quality of life, affecting their daily routines, work, and...

Mastering pediatric asthma clinical trials

PediatricRespiratory
Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of life instruments. Asthma clinical research...

Ophthalmology Clinical Trials

Ophthalmology
Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally: Data collection can be very challenging for patients with...

How Kayentis Helps You Manage The Growing Complexities Of eCOA Trials

Project management
We all know clinical trials are more and more complex, involving an increasing number of systems, multiple populations, and an...

Rare Disease case study

Rare disease
Over 90% of rare diseases have no treatment…  There are more than 6,000 known rare diseases... Approximately 80% of them have...

Tackling the complexity of pediatric clinical trials

Pediatric
Despite the evolution in pediatric legislation and a renewed interest in developing therapeutics for pediatric and rare diseases, pediatric clinical...

Big Pharma Case Study

Project management
Kayentis has more than eighteen years of success stories with Big Pharma, and has been helping Big Pharma mitigate clinical...

Immunology Case Study

Immuno-Inflammation
Immunology studies present specific challenges: their eCOA build can be complex, site staff must play a key role, and study...

Kayentis & RWS partnering for success

Project management
Kayentis (global provider of eCOA and DCT solutions) and RWS (language service provider (LSP) and linguistic validation experts) were selected...

Oncology Case Study

Oncology
Oncology studies present specific challenges that generate complex eCOA build and management: complex study design, frequent amendments, and long study...

Dermatology Case Study

Dermatology
Kayentis offers extensive expertise in dermatology and a solid experience with several typical PROs, ClinROs and Patient Diaries.With a large...

Kayentis supports the 1st personalized immunotherapy treatment approved by both FDA & EMA

Immuno-Inflammation
Acute Lymphoblastic or Lymphoid Leukemia (ALL) is a cancer of the lymphocytes that can result in serious complications such as...
Follow us on social media
Subscribe to our newsletter
You may also like

Rare disease clinical research: it is time to tackle what...

Biotech and eCOA vendor: A shared mindset

The client’s voice: why they consistently choose Kayentis

Why you should join Kayentis

Rethinking pediatric clinical trials: guidelines from pediatric experts

Overcoming challenges in long-lasting pediatric clinical trials – Insights from...

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA